Why it may matterVerify against the original reporting
Near-term execution-driven stock move due to earnings beat offset by post-earnings PT revisions and a 5.8% drop; valuation remains sensitive to how 2026 guidance translates into cash flow and margin realization.
AI summary
What happened, with direct paths to the underlying reporting
Intuitive Surgical beat on revenue and earnings due to broad adoption across da Vinci platforms. The company guided 2026 worldwide da Vinci procedures to grow 14-15% with margins around 68.7-69.3%, supporting durable profitability. However, shares declined about 5-6% as investors digest changes to price targets from several analysts.
ISRG Q3 revenue $3.05B, above $2.91B estimate.
Q3 adjusted EPS $3.00, vs $2.64 estimate.
2026 da Vinci procedures growth guided to 14-15%; gross margin 68.7-69.3%.
Shares fell 5.8% to $413.12 after results; multiple PT revisions.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Intuitive Surgical posted Q2 results above consensus with EPS of $2.80 on $2.89B revenue, beating estimates of $2.50 and $2.82B. Management highlighted strength across da Vinci, I…
Intuitive Surgical (ISRG) exhibited strong earnings that indicate continued growth potential. The rising adoption of robotic surgery systems suggests an increase in surgical proce…
Intuitive Surgical exceeded revenue and earnings expectations for Q4. However, the anticipated growth rate for da Vinci procedures is slowing down, with analysts adjusting price t…
Intuitive Surgical's strong Q4 2025 results feature better-than-expected EPS and revenue growth, driven by an increase in da Vinci procedures. However, the 2026 guidance suggests…